Related Experiment Video
Updated: Dec 31, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive
Safi U Khan1, Muhammad U Khan1, Haris Riaz2
1Department of Medicine, West Virginia University, Morgantown, West Virginia.
Insights
Intensive cholesterol-lowering therapy may offer greater cardiovascular benefits for individuals with normal body mass index (BMI). Obese patients might experience reduced therapy efficacy or a true therapeutic limitation.
Area of Science:
- Cardiology
- Metabolic Health
- Clinical Trials
Background:
- The effect of body mass index (BMI) on cardiovascular outcomes during intensive low-density lipoprotein cholesterol (LDL-C) lowering therapy remains unclear.
- Understanding this relationship is crucial for optimizing treatment strategies.
Purpose of the Study:
- To investigate the association between BMI and cardiovascular outcomes in patients undergoing intensive LDL-C lowering therapy.
- To compare the efficacy of more intensive versus less intensive LDL-C lowering regimens across different BMI categories.
Main Methods:
- A meta-analysis of 29 randomized controlled trials was conducted, including data up to April 2019.
- Therapies were categorized into more intensive (e.g., statins, PCSK9 inhibitors) and less intensive (placebo or less potent agents) LDL-C lowering.
- Random effects meta-regressions evaluated the link between BMI and cardiovascular endpoints in 265,766 patients.
Main Results:
- Higher BMI was associated with increased risks of cardiovascular mortality (HR 1.07), all-cause mortality (HR 1.03), myocardial infarction (HR 1.06), revascularization (HR 1.08), and major adverse cardiovascular events (MACE) (HR 1.04) per 1 kg/m² BMI increase with intensive therapy.
- Patients with BMI <25 kg/m² demonstrated the greatest risk reduction in mortality and cardiovascular outcomes compared to those with BMI ≥30 kg/m² (p-interaction ≤0.05).
Conclusions:
- Intensive LDL-C lowering therapy may provide greater clinical benefits for patients with normal BMI compared to those with higher BMI.
- Potential explanations include masking of therapy efficacy by higher obese patient mortality or genuine therapeutic limitations in this group.
Abstract:
The impact of body mass index (BMI) on cardiovascular outcomes in patients receiving intensive low-density lipoprotein cholesterol (LDL-C) lowering therapy is uncertain. We performed meta-analysis of 29 randomized controlled trials using PubMed, Embase, and CENTRAL through April 2019. Therapies were grouped as more intensive LDL-C lowering therapy (statins, ezetimibe + statin or PCSK9 inhibitors) and less intensive LDL-C lowering therapy (less potent active control or placebo). Random effects meta-regressions and meta-analyses were performed to evaluate association of BMI with cardiovascular endpoints. In 265,766 patients, for every 1 kg/m2 increase in BMI, more intensive therapy compared with less intensive therapy was associated with hazard ratio (HR) of 1.07 for cardiovascular mortality (95% confidence interval 1.02 to 1.13); HR of 1.03 for all-cause mortality (0.99 to 1.06) HR of 1.06 for myocardial infarction (1.02 to 1.09), HR of 1.08 (1.03 to 1.12) for revascularization and HR of 1.04 for MACE (1.01 to 1.07). Meta-analysis showed that patients with BMI <25 kg/m2 had the highest risk reduction in mortality and cardiovascular outcomes compared with patients with BMI ≥30 kg/m2 (p-interaction ≤0.05). In conclusion, patients with normal BMI treated with intensive LDL-C lowering regimens may derive a larger clinical benefit compared with patients with larger BMI. The results could be due to the higher mortality rate of obese patients that may artificially lower the efficacy of therapy, or due to a true therapeutic limitation in these patients.
More Related Videos
03:05Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
Published on: November 21, 2025
06:04Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
Related Concept Videos
Atherosclerosis III: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease IV: Preventive Measures
Drug Dosing: Obese Patients
Cholesterol: Significance and Regulation
Considering cholesterol and...